Skip to main
SEPN
SEPN logo

Septerna Inc (SEPN) Stock Forecast & Price Target

Septerna Inc (SEPN) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Septerna Inc. has demonstrated a commitment to refining its drug development processes, leveraging its prior experience with the candidate SEP-786 to enhance the efficiency of its Phase 1 clinical trials. The company’s focus on its proprietary Native Complex Platform, combined with promising data from preclinical testing indicating a potentially improved profile for its candidates, supports a positive outlook. Furthermore, the successful restoration of calcium/phosphate balance in TPTx rat models using low-dose oral dosing for SEP-479 further validates the therapeutic potential of Septerna's pipeline in addressing unmet medical needs in endocrinology, immunology, and metabolic diseases.

Bears say

Septerna Inc faces significant challenges that may negatively impact its stock outlook, including its status as a clinical-stage biotechnology company, which inherently carries high risks associated with drug development and regulatory approval processes. The reliance on a proprietary platform for GPCR drug discovery may not guarantee successful outcomes in a competitive market, particularly when the therapeutic pipeline remains unproven in terms of clinical efficacy and market acceptance. Additionally, the concentrated focus on three therapeutic areas may limit diversification and growth potential, further elevating investment risk amid uncertainty regarding future funding and operational sustainability.

Septerna Inc (SEPN) has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Septerna Inc (SEPN) Forecast

Analysts have given Septerna Inc (SEPN) a Buy based on their latest research and market trends.

According to 4 analysts, Septerna Inc (SEPN) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Septerna Inc (SEPN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.